Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.

Support the show